Literature DB >> 20488222

Comparative pharmacokinetics of some injectable preparations containing ivermectin in dogs.

Gökhan Eraslan1, Murat Kanbur, Bilal Cem Liman, Yücel Cam, Mürsel Karabacak, Sule Altinordulu.   

Abstract

Little is known about the kinetics of ivermectin formulations following subcutaneous administration in dogs. The vehicle components used in production may change the pharmacokinetics of the drug. The present study was aimed at the comparison of the pharmacokinetics of seven injectable ivermectin formulation of different brand names (A-G). The animals were allocated to seven groups, each comprising seven dogs. The dogs were administered ivermectin at a dose of 200 microg/kg bw by subcutaneous route and blood samples were collected from all groups up to 288h post-injection. Plasma ivermectin analyses were performed using a HPLC with a fluorescence detector. Compared to Group 1(A), it was determined that statistically significant differences existed in Groups 2(B), 3(C), 4(D), 5(E), and 7(G) for C(max) values; and in Groups 3(C), 4(D), 6(F), 7(G) for AUC(0-->288) and AUC(0-->infinity) values. These values were highest in Group 1(A) and lowest in Group 7(F). The results obtained in the present study demonstrated that, in cases which require subacute administration, optimal exposure is achieved with the preparation A. However, it must be noted that this evaluation was based on pharmacokinetic parameters and not antiparasitic efficacy. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20488222     DOI: 10.1016/j.fct.2010.05.043

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  7 in total

Review 1.  Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of P-glycoprotein in dogs and cats.

Authors:  Valentina M Merola; Paul A Eubig
Journal:  Vet Clin North Am Small Anim Pract       Date:  2012-03       Impact factor: 2.093

2.  Concurrent infestation of Notoedres, Sarcoptic and Psoroptic acariosis in rabbit and its management.

Authors:  P N Panigrahi; B N Mohanty; A R Gupta; R C Patra; S Dey
Journal:  J Parasit Dis       Date:  2014-12-20

3.  Ivermectin-loaded lipid nanocapsules: toward the development of a new antiparasitic delivery system for veterinary applications.

Authors:  G V Ullio Gamboa; S D Palma; A Lifschitz; M Ballent; C Lanusse; C Passirani; J P Benoit; D A Allemandi
Journal:  Parasitol Res       Date:  2016-02-06       Impact factor: 2.289

4.  Screening for an ivermectin slow-release formulation suitable for malaria vector control.

Authors:  Carlos Chaccour; Ángel Barrio; Ana Gloria Gil Royo; Diego Martinez Urbistondo; Hannah Slater; Felix Hammann; Jose Luis Del Pozo
Journal:  Malar J       Date:  2015-03-05       Impact factor: 2.979

5.  A quick and simple method for the determination of ivermectin in dog plasma by LC-MS/MS.

Authors:  Eva Morbidelli; Julie Rambaldi; Laura Ricci Bitti; Anna Zaghini; Andrea Barbarossa
Journal:  MethodsX       Date:  2018-11-17

Review 6.  Current therapeutic applications and pharmacokinetic modulations of ivermectin.

Authors:  Khan Sharun; T S Shyamkumar; V A Aneesha; Kuldeep Dhama; Abhijit Motiram Pawde; Amar Pal
Journal:  Vet World       Date:  2019-08-08

7.  Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats.

Authors:  Carlos Chaccour; Gloria Abizanda; Ángel Irigoyen-Barrio; Aina Casellas; Azucena Aldaz; Fernando Martínez-Galán; Felix Hammann; Ana Gloria Gil
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.